SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $6.00 price target on the stock.

Separately, Chardan Capital reaffirmed a buy rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $4.72 on Tuesday. SAB Biotherapeutics has a 12 month low of $4.00 and a 12 month high of $14.50. The company has a 50-day moving average of $4.96 and a 200-day moving average of $3.11. The company has a quick ratio of 5.45, a current ratio of 5.45 and a debt-to-equity ratio of 0.06.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SABS. RTW Investments LP acquired a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $6,310,000. BVF Inc. IL acquired a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $6,310,000. Commodore Capital LP acquired a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $1,259,000. Pathstone Family Office LLC purchased a new position in SAB Biotherapeutics in the 3rd quarter worth approximately $319,000. Finally, Pathstone Holdings LLC purchased a new position in SAB Biotherapeutics in the 4th quarter worth approximately $348,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.